Skip to main content
Weiter zur Homepage der Europäischen Kommission (öffnet in neuem Fenster)
Deutsch de
CORDIS - Forschungsergebnisse der EU
CORDIS

Enzymatic STEreospecific RNA phosphorothioate modification for next-generation therapeutics

Ziel

RNA therapeutics have emerged as a powerful medical modality, from COVID-19 vaccines to treatments for rare genetic diseases and cancer. However, a fundamental bottleneck limits their potential: RNA instability. Most approved RNA drugs rely on phosphorothioate (PS) modifications for stability and delivery, but current chemical synthesis produces stereochemical mixtures reducing efficacy, increasing toxicity, and complicating regulatory approval. Moreover, chemical PS synthesis is restricted to short RNAs, completely excluding therapeutic mRNAs from site-specific backbone optimization despite evidence that strategic PS placement can dramatically enhance translation efficiency. This represents a fundamental technological gap constraining millions of patients with rare genetic diseases and cancer needing personalized immunotherapies from accessing safer and more effective RNA medicines.
Our ERC-funded discovery revealed the first naturally occurring stereospecific RNA PS modifications and the enzyme family responsible for their installation. This breakthrough provides a biological route to manufacturing next-generation RNA therapeutics, simultaneously eliminating stereochemical heterogeneity, enabling cost-effective stereopure synthesis (≥10x cheaper), and uniquely installing site-specific PS modifications in full-length mRNAs.
This PoC will advance our technology from TRL 3 to TRL 4 through three objectives targeting industrial readiness: 1) we will demonstrate scalable enzymatic PS installation to produce stereopure modified RNA, 2) we will engineer programmable substrate specificity to create variants targeting therapeutic ASOs and mRNAs and 3) we will demonstrate commercial feasibility through techno-economic analysis and engagement with RNA therapeutics companies. Our success will address the unmet patient needs while unlocking market opportunities in the $6.5B ASO therapeutics and $11.4B mRNA therapeutics markets currently constrained by manufacturing limitations

Wissenschaftliches Gebiet (EuroSciVoc)

Programm/Programme

Thema/Themen

Finanzierungsplan

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

Alle im Rahmen dieses Finanzierungsinstruments finanzierten Projekte anzeigen

Aufforderung zur Vorschlagseinreichung

(öffnet in neuem Fenster) ERC-2026-POC

Alle im Rahmen dieser Aufforderung zur Einreichung von Vorschlägen finanzierten Projekte anzeigen

Gastgebende Einrichtung

WEIZMANN INSTITUTE OF SCIENCE
Netto-EU-Beitrag
€ 150 000,00
Gesamtkosten
Keine Daten

Begünstigte (1)